Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Capital Expenditures (2020 - 2025)

Bolt Biotherapeutics (BOLT) has disclosed Capital Expenditures for 6 consecutive years, with $72000.0 as the latest value for Q3 2025.

  • Quarterly Capital Expenditures rose 1700.0% to $72000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $76000.0 through Dec 2025, up 85.37% year-over-year, with the annual reading at $72000.0 for FY2025, 75.61% up from the prior year.
  • Capital Expenditures hit $72000.0 in Q3 2025 for Bolt Biotherapeutics, up from $4000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $1.8 million in Q4 2022 to a low of -$755000.0 in Q4 2021.
  • Historically, Capital Expenditures has averaged $231357.1 across 5 years, with a median of $59000.0 in 2023.
  • Biggest five-year swings in Capital Expenditures: tumbled 170.03% in 2022 and later surged 1700.0% in 2025.
  • Year by year, Capital Expenditures stood at -$755000.0 in 2021, then surged by 334.57% to $1.8 million in 2022, then crashed by 102.71% to -$48000.0 in 2023, then skyrocketed by 108.33% to $4000.0 in 2024, then soared by 1700.0% to $72000.0 in 2025.
  • Business Quant data shows Capital Expenditures for BOLT at $72000.0 in Q3 2025, $4000.0 in Q3 2024, and $37000.0 in Q2 2024.